Efficacy of Methylprednisolone With DexamethasoneiIn patients With Severe Covid Pneumonia
Abstract
Aim: Efficacy of Methylprednisolone with Dexamethasone in patients with severe COVID pneumonia in term of clinical and biochemical improvement. Methodology: Cross Sectional analytical study conducted among COVID-19 patients admitted in HDU of Sir Sadiq Hospital, Bahawalpur from May, 2021 to June 2021 after taking approval from institutional ethical committee. 82 patients were included in this study after taking informed consent. Patients were divided into two groups A and B i.e. I/V methyl prednisolone and I/V dexamethasone respectively. Each group was containing 41 patients. Primary outcome was measured in terms of decrease or increase in oxygen demand leading to discharge or shifting to Intensive Care Unit. CRP levels were also measured to assess biochemical improvement. Results: 31 (75.6%) patients from group A and 22(53.7%) from group B were improved and discharged and difference was statistically significant (p<0.05). Number of patients shifted to ICU were 10(24.4%) and 19(46.3%) from A and B groups respectively. Conclusion: In terms of clinical and biochemical response methylprednisolone outperforms dexamethasone. Keywords: Methylprednisolone, Dexamethasone, COVID pneumonia,
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.